A world where genetic advantage becomes another form of inequality
At fertility clinics across the country, prospective parents can now select embryos based on statistical predictions of disease risk and human traits — a capability that has arrived not with fanfare but with the quiet momentum of technologies that reshape what we take for granted. The science, built on probabilistic models and imperfect data, is far less certain than the services marketing it suggest. Ethicists, physicians, and policymakers find themselves watching a threshold being crossed — between medicine and optimization, between preventing suffering and purchasing advantage — without a shared agreement on where that line should fall.
- Fertility clinics are already offering embryo selection based on polygenic risk scores that predict susceptibility to hundreds of conditions, as well as traits like height and intelligence — making the once-theoretical prospect of trait selection a present commercial reality.
- The predictive models underlying these scores are built largely on European ancestry data, making them unreliable for individuals and even less accurate for people from underrepresented populations, meaning consequential decisions rest on genuinely uncertain ground.
- Access to the full IVF-plus-screening process costs tens of thousands of dollars, raising the alarm that genetic advantage could become yet another dimension of inequality — one that compounds across generations and proves nearly impossible to reverse.
- Medical experts warn of deeper risks: reduced genetic diversity, the psychological burden on children who know they were selected for predicted traits, and a social pressure dynamic where opting out of screening may come to feel like withholding opportunity.
- Regulatory and ethical frameworks have not kept pace — the technology is expanding, more families are using it, and the societal conversation about where medicine ends and human enhancement begins has barely started.
The technology arrived without announcement, the way most transformative things do. Fertility clinics now offer parents the ability to examine embryos before implantation and choose among them based on predictions about disease risk and the likelihood of specific traits. It is not quite designer babies — the science is far messier than that phrase implies — but it is close enough to make ethicists, doctors, and policymakers deeply uneasy.
The process relies on polygenic risk scoring: an embryo's DNA is analyzed to calculate statistical probabilities of developing heart disease, diabetes, Alzheimer's, and hundreds of other conditions. The same analysis can estimate odds for height, educational attainment, and intelligence. Companies market these tools as instruments for preventing suffering. The reality is more complicated.
Accuracy is the first concern. These models are built on population-level data, mostly from people of European ancestry, and they perform poorly when applied to individuals or to people whose genetic backgrounds differ from the training data. A score suggesting a 40 percent lifetime risk of heart disease is probabilistic and uncertain — yet parents making irreversible decisions often treat it as something more definitive than it is.
Access is the second. The full process costs tens of thousands of dollars, placing it within reach primarily of wealthy families. The worry is not that the technology creates inequality, but that it could entrench and deepen it — making genetic advantage one more thing money can buy across generations.
The third concern is harder to name. Screening embryos for cystic fibrosis feels like medicine. Screening for predicted intelligence or height feels like something else — like optimization, like shopping. And once the option exists, the pressure to use it grows. Parents who decline may feel they are withholding advantages others have purchased. Collectively, millions of small choices could quietly reshape what it means to be human.
Experts urge caution: the science is young, gene-environment interactions are poorly understood, and selecting for certain traits may inadvertently reduce the genetic diversity that protects populations from disease. The children selected may also carry a particular psychological weight — knowing they were chosen, in part, for their predicted traits.
None of this is slowing the industry. Services are expanding, the science is improving, and more families are using it. The question is no longer whether this will happen — it already is. The question is whether societies will find the will to govern it before the moment for meaningful choice has passed.
The technology arrived quietly, the way most transformative things do. Fertility clinics across the country now offer prospective parents something that seemed like science fiction a decade ago: the ability to examine embryos before implantation and choose among them based on predictions about disease risk and the likelihood of specific traits. It is not quite designer babies—the science is far messier than that phrase suggests—but it is close enough to make ethicists, doctors, and policy makers deeply uncomfortable.
The screening works through a process called polygenic risk scoring. Geneticists analyze an embryo's DNA and calculate the statistical probability that it will develop heart disease, diabetes, certain cancers, Alzheimer's disease, and hundreds of other conditions. The same analysis can estimate odds for traits like height, educational attainment, and intelligence. Parents can then select embryos that score favorably on whichever measures matter most to them. The companies offering these services market them as tools for preventing suffering. The reality is more complicated.
The first problem is accuracy. Polygenic risk scores are built on data from large populations, mostly of European ancestry. They work reasonably well at predicting risk across groups—they can identify which people in a population are more likely to develop a disease. But they are far less reliable for individuals, and they are even less reliable for people whose genetic ancestry differs from the populations used to build the models. A score that says an embryo has a 40 percent lifetime risk of heart disease does not mean that embryo will definitely develop heart disease, or that it will not. It means something probabilistic, something uncertain. Parents making irreversible decisions about which embryos to implant are often working with information that feels precise but is actually quite fuzzy.
The second problem is access. Embryo screening through in vitro fertilization is expensive—the full process costs tens of thousands of dollars. It is available primarily to wealthy families in wealthy countries. This creates a troubling possibility: a world in which genetic advantage becomes another form of inequality, where the rich can purchase embryos selected for lower disease risk and higher predicted intelligence, while everyone else cannot. The technology does not create this inequality, but it could deepen it in ways that are difficult to reverse.
The third problem is harder to name but perhaps most important. It concerns the line between medicine and enhancement, between treating disease and optimizing human traits. Screening for embryos at high risk of cystic fibrosis or sickle cell disease feels like medicine—preventing serious suffering. But screening for height or intelligence or educational potential feels different. It feels like shopping. And once the technology exists, the pressure to use it intensifies. Parents who do not screen might feel they are denying their children advantages that others have purchased. The collective choice to use the technology could reshape what it means to be human, not through any single decision but through millions of small ones.
Medical experts are urging caution. They point out that the science is still young, that we do not fully understand how genes interact with environment and chance, that predicting complex traits from DNA alone is far harder than predicting simple ones. They worry about unintended consequences—that selecting for certain traits might inadvertently select against genetic diversity that protects populations from disease. They worry about the psychological weight of being a child selected for specific traits, of carrying the knowledge that your parents chose you partly because of your predicted intelligence or appearance.
None of this means the technology will slow down. The companies offering embryo screening are expanding their services. The science is improving, slowly but steadily. More parents are using it. The question now is not whether this will happen—it is already happening—but whether societies will develop rules to govern it. That conversation has barely begun.
Citas Notables
Medical experts are urging caution, pointing out that the science is still young and that predicting complex traits from DNA alone is far harder than predicting simple ones— Medical experts and ethicists
La Conversación del Hearth Otra perspectiva de la historia
When you say parents can screen for traits like intelligence, what does that actually mean? Can they really predict that from DNA?
Not with any real precision. The science takes data from large studies showing that certain genetic variants are statistically associated with higher educational attainment or test scores. But those associations are weak, and they only work at the population level. For any individual embryo, the prediction is fuzzy.
So a parent might select an embryo thinking they're getting a smarter child, but the science doesn't really support that?
Exactly. And worse, the predictions work best for people of European ancestry because that's whose DNA is in most of the databases. For everyone else, the predictions are even less reliable.
That sounds like it could make inequality worse.
It almost certainly will. In vitro fertilization with genetic screening costs tens of thousands of dollars. Only wealthy families can access it. If the wealthy can purchase embryos selected for lower disease risk and higher predicted traits, and everyone else cannot, you're creating a genetic class system.
But screening for serious diseases like cystic fibrosis seems different from screening for height.
It does, and most people would agree. But once the technology exists and works for disease, the pressure to use it for other things becomes almost irresistible. Parents start asking: why wouldn't I want to know? Why wouldn't I want to choose?
What happens to the embryos that don't get selected?
That's another question people don't talk about enough. They're either frozen indefinitely or discarded. There are real ethical questions there about what we're doing.